1. Home
  2. NAMS vs SKWD Comparison

NAMS vs SKWD Comparison

Compare NAMS & SKWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • SKWD
  • Stock Information
  • Founded
  • NAMS 2019
  • SKWD 2007
  • Country
  • NAMS Netherlands
  • SKWD United States
  • Employees
  • NAMS N/A
  • SKWD N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • SKWD Property-Casualty Insurers
  • Sector
  • NAMS Health Care
  • SKWD Finance
  • Exchange
  • NAMS Nasdaq
  • SKWD Nasdaq
  • Market Cap
  • NAMS 2.5B
  • SKWD 2.4B
  • IPO Year
  • NAMS N/A
  • SKWD 2023
  • Fundamental
  • Price
  • NAMS $17.96
  • SKWD $57.33
  • Analyst Decision
  • NAMS Strong Buy
  • SKWD Buy
  • Analyst Count
  • NAMS 8
  • SKWD 12
  • Target Price
  • NAMS $42.88
  • SKWD $63.88
  • AVG Volume (30 Days)
  • NAMS 893.6K
  • SKWD 305.5K
  • Earning Date
  • NAMS 08-06-2025
  • SKWD 08-04-2025
  • Dividend Yield
  • NAMS N/A
  • SKWD N/A
  • EPS Growth
  • NAMS N/A
  • SKWD 9.29
  • EPS
  • NAMS N/A
  • SKWD 2.98
  • Revenue
  • NAMS $47,140,000.00
  • SKWD $1,213,759,000.00
  • Revenue This Year
  • NAMS N/A
  • SKWD $18.33
  • Revenue Next Year
  • NAMS N/A
  • SKWD $11.61
  • P/E Ratio
  • NAMS N/A
  • SKWD $19.24
  • Revenue Growth
  • NAMS 586.97
  • SKWD 26.30
  • 52 Week Low
  • NAMS $14.06
  • SKWD $34.10
  • 52 Week High
  • NAMS $27.29
  • SKWD $65.05
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 42.30
  • SKWD 40.75
  • Support Level
  • NAMS $20.06
  • SKWD $56.96
  • Resistance Level
  • NAMS $21.91
  • SKWD $59.79
  • Average True Range (ATR)
  • NAMS 1.41
  • SKWD 1.90
  • MACD
  • NAMS -0.20
  • SKWD -0.76
  • Stochastic Oscillator
  • NAMS 4.45
  • SKWD 4.57

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.

Share on Social Networks: